tradingkey.logo
๎™

Neuronetics Inc

STIM
๎˜น
์ƒ์„ธ ์ฐจํŠธ ๋ณด๊ธฐ
1.560USD
+0.140+9.86%
์ข…๊ฐ€ย 02/06, 16:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
106.77M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™
Intraday
1m
30m
1h
D
W
M
D

์˜ค๋Š˜

+9.86%

5์ผ

-25.36%

1๊ฐœ์›”

-7.69%

6๊ฐœ์›”

-63.25%

์˜ฌํ•ด ํ˜„์žฌ๊นŒ์ง€

+13.04%

1๋…„

-56.18%

์ƒ์„ธ ์ฐจํŠธ ๋ณด๊ธฐ

TradingKey Neuronetics Inc ์ฃผ์‹ ์ ์ˆ˜๎˜

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2026-02-06

์ฃผ์š” ์ธ์‚ฌ์ดํŠธ

Neuronetics Inc์˜ ํŽ€๋”๋ฉ˜ํ„ธ์€ ๋น„๊ต์  ์•ˆ์ •์  ์ƒํƒœ์ด๋ฉฐ, ESG ๊ณต์‹œ๋Š” ์—…๊ณ„๋ฅผ ์„ ๋„ํ•˜๋Š” ์ˆ˜์ค€์ž…๋‹ˆ๋‹ค.์„ฑ์žฅ ์ž ์žฌ๋ ฅ์€ ๋†’์Šต๋‹ˆ๋‹ค.๊ธฐ์—…์˜ ๋ฐธ๋ฅ˜์—์ด์…˜์€ ์ ์ •ํ•˜๊ฒŒ ํ‰๊ฐ€๋œ ๊ฒƒ์œผ๋กœ ๊ฐ„์ฃผ๋˜๋ฉฐ, ์˜๋ฃŒ ์žฅ๋น„ ๋ฐ ๊ณต๊ธ‰ํ’ˆ ์‚ฐ์—…์—์„œ 205๊ฐœ ์ค‘ 89์œ„ ๋žญํ‚น.๊ธฐ๊ด€ ๋ณด์œ  ๋น„์œจ์€ ๋งค์šฐ ๋†’์€.์ง€๋‚œ ํ•œ ๋‹ฌ ๋™์•ˆ ์—ฌ๋Ÿฌ ์• ๋„๋ฆฌ์ŠคํŠธ๊ฐ€ ํ•ด๋‹น ๊ธฐ์—…์„ ๋งค์ˆ˜(์œผ)๋กœ ํ‰๊ฐ€ํ–ˆ์œผ๋ฉฐ, ์ตœ๊ณ  ๋ชฉํ‘œ ๊ฐ€๊ฒฉ์€ 6.50์ž…๋‹ˆ๋‹ค.์ค‘๊ธฐ์ ์œผ๋กœ ์ฃผ๊ฐ€๋Š” ํ•˜๋ฝ ์ถ”์„ธ์ผ ๊ฒƒ์œผ๋กœ ์˜ˆ์ƒ๋ฉ๋‹ˆ๋‹ค.์ง€๋‚œ ํ•œ ๋‹ฌ๊ฐ„ ์ฃผ์‹ ์‹œ์žฅ์—์„œ ๋งค์šฐ ๋ถ€์ง„ํ•œ ์„ฑ๊ณผ๋ฅผ ๊ฑฐ๋‘์—ˆ์ง€๋งŒ, ๊ธฐ์—…์˜ ํŽ€๋”๋ฉ˜ํ„ธ๊ณผ ๊ธฐ์ˆ ์  ์ง€ํ‘œ๋Š” ํƒ„ํƒ„ํ•ฉ๋‹ˆ๋‹ค.์ฃผ๊ฐ€๋Š” ์ง€์ง€์„ ๊ณผ ์ €ํ•ญ์„  ์‚ฌ์ด์—์„œ ํšก๋ณดํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ๋ฒ”์œ„ ๋งค๋งค ๊ธฐ๋ฐ˜์˜ ์Šค์œ™ ํŠธ๋ ˆ์ด๋”ฉ์— ์ ํ•ฉํ•œ ์ƒํ™ฉ์ž…๋‹ˆ๋‹ค.

Neuronetics Inc ์ ์ˆ˜๎˜ฐ๎˜ฐ

๊ด€๋ จ ์ •๋ณด

์‚ฐ์—… ์ˆœ์œ„
89 / 205
์ „์ฒด ์ˆœ์œ„
239 / 4521
์‚ฐ์—…
์˜๋ฃŒ ์žฅ๋น„ ๋ฐ ๊ณต๊ธ‰ํ’ˆ

์ €ํ•ญ์„  & ์ง€์ง€์„ 

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

๋ ˆ์ด๋” ์ฐจํŠธ

ํ˜„์žฌ ๊ฐ€๊ฒฉ
๊ณผ๊ฑฐ

๋ฏธ๋””์–ด ๋ณด๋„

์ตœ๊ทผ 24 ์‹œ๊ฐ„
๋ณด๋„ ์ˆ˜์ค€

๋งค์šฐ ๋‚ฎ์€
๋งค์šฐ ๋†’์€
์ค‘๋ฆฝ

Neuronetics Inc ์ฃผ์š” ๋‚ด์šฉ

๊ฐ•์ ์œ„ํ—˜ ์š”์†Œ
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Companyโ€™s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individualโ€™s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
์„ฑ์žฅ ์ค‘
ํšŒ์‚ฌ๋Š” ์„ฑ์žฅ ๋‹จ๊ณ„์— ์žˆ์œผ๋ฉฐ, ์ตœ์‹  ์—ฐ๊ฐ„ ์ˆ˜์ต์€ ๋ฏธํ™” 74.89M์— ๋‹ฌํ•ฉ๋‹ˆ๋‹ค.
๊ณ ์ˆ˜์ต ์„ฑ์žฅ
ํšŒ์‚ฌ์˜ ์ˆœ์ด์ต์€ ์—…๊ณ„ ์„ ๋‘๋ฅผ ๋‹ฌ๋ฆฌ๊ณ  ์žˆ์œผ๋ฉฐ, ์ตœ๊ทผ ์—ฐ๊ฐ„ ์ˆœ์ด์ต์€ ๋ฏธํ™” 74.89M์— ๋‹ฌํ•ฉ๋‹ˆ๋‹ค.
๊ณต์ •ํ•œ ๊ฐ€์น˜
ํšŒ์‚ฌ์˜ ์ตœ์‹  PE์€ -1.88๋กœ, ์ตœ๊ทผ 3๋…„ ๊ธฐ์ค€ ์ค‘๊ฐ„ ๋ฐฑ๋ถ„์œ„ ๋ฒ”์œ„์— ์†ํ•ฉ๋‹ˆ๋‹ค.
๊ธฐ๊ด€ ๋งค๋„
์ตœ์‹  ๊ธฐ๊ด€ ๋ณด์œ  ์ฃผ์‹ ์ˆ˜๋Š” 42.40M์ฃผ์ด๋ฉฐ, ์ „ ๋ถ„๊ธฐ ๋Œ€๋น„ 26.69% ๊ฐ์†Œํ–ˆ์Šต๋‹ˆ๋‹ค.
Invesco๊ฐ€ ๋ณด์œ 
์Šคํƒ€ ํˆฌ์ž์ž Invesco์ด(๊ฐ€) ์ด ์ฃผ์‹ 13.74K์ฃผ๋ฅผ ๋ณด์œ ํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค.
์‹œ์žฅ ํ™œ๋™ ์ฆ๊ฐ€
ํšŒ์‚ฌ๋Š” ํˆฌ์ž์ž๋“ค์˜ ๊ด€์‹ฌ์ด ๋†’์•„์ ธ, ์ตœ๊ทผ 20์ผ๊ฐ„ ํšŒ์ „์œจ์ด 0.95์ž…๋‹ˆ๋‹ค.

๋ถ„์„๊ฐ€ ๋ชฉํ‘œ๊ฐ€

3 ๋ช…์˜ ๋ถ„์„๊ฐ€๋ฅผ ๊ธฐ์ค€์œผ๋กœ
๋งค์ˆ˜
ํ˜„์žฌ ๋“ฑ๊ธ‰
6.500
๋ชฉํ‘œ ๊ฐ€๊ฒฉ
+357.75%
์ƒ์Šน ์—ฌ๋ ฅ
๋ฉด์ฑ… ์กฐํ•ญ: ์• ๋„๋ฆฌ์ŠคํŠธ ํ‰๊ฐ€ ๋ฐ ๋ชฉํ‘œ ์ฃผ๊ฐ€๋Š” ์ •๋ณด ์ œ๊ณต์„ ์œ„ํ•œ ๋ชฉ์ ์œผ๋กœ LSEG์—์„œ ์ œ๊ณต๋˜๋ฉฐ, ํˆฌ์ž ์กฐ์–ธ์œผ๋กœ ๊ฐ„์ฃผ๋˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.

Neuronetics Inc ๋‰ด์Šค

๋” ๋งŽ์€ ๋‰ด์Šค๊ฐ€ ๊ณง ์—…๋ฐ์ดํŠธ๋ฉ๋‹ˆ๋‹ค. ๊ณ„์† ์ง€์ผœ๋ด ์ฃผ์„ธ์š”โ€ฆ

์žฌ๋ฌด ์ง€ํ‘œ๎˜

EPS

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ด ์ˆ˜์ต

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

Neuronetics Inc ์ •๋ณด๎˜

Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Companyโ€™s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individualโ€™s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
์ข…๋ชฉ ์ฝ”๋“œ STIM
ํšŒ์‚ฌNeuronetics Inc
CEOMr. Keith J. Sullivan
์›น์‚ฌ์ดํŠธhttps://neurostar.com/neuronetics/
KeyAI
๎™